Miraca Life Sciences Registry

Miraca Life Sciences Registry - Advancing Cancer Research

What is the Miraca Life Sciences Registry?

Miraca Life Sciences Patient Registry of Hematopoietic Diseases is a multi-center, observational outcomes database designed to collect data on the demographics, presentation, diagnosis, treatment, resource use, and outcomes of eligible patients who previously have undergone Miraca Life Sciences hematopoietic diagnostics testing.

By contributing patients’ data, the medical community may gain insights into patient management for specific hematopoietic diseases.

What are the features & benefits of the Miraca Life Sciences Registry?

  • The Miraca Life Sciences Registry does not require any change to the way the physician manages his/her patient.
  • Registry data is entered into a user-friendly, online portal, accessible 24/7.
  • Subjects enrolled in the Registry count toward meeting ACoS Cancer Program Research accrual requirements.
  • WIRB-approved verbal consent model.
  • No quotas/volume requirements to fulfill.
  • All Registry data required is already in your patients’ clinical medical records.

Participation guidelines have been separately determined by the Miraca Life Sciences Registry team, pursuant to a protocol which has been approved by an independent Institutional Review Board (IRB).

How does the Miraca Life Sciences Registry work?

Detailed data from hematopoietic diagnostic testing completed at Miraca Life Sciences is integrated with patients’ clinical data (demographics, diagnostic, prognostic, treatment and outcome data). This information is collected and tracked over time in three intervals: enrollment, one year and five years/off-study.

Who is considered an “eligible patient”?

Bone marrow and comprehensive peripheral blood cases are invited for enrollment into the Miraca Life Sciences Registry if the following minimum inclusion criteria are met:

  • Morphology
  • Minimum of 3 technologies
    • IHC
    • Flow Cytometry
    • FISH
    • Cytogenetics
    • PCR
    • Sequencing
  • Working Clinical Diagnosis is included in one of the following disease categories:
    • Plasma Cell Neoplasms
    • Myelodysplastic Syndromes (MDS) and Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN)
    • Acute leukemias
    • Myeloproliferative Disorders
    • Lymphomas

Participation in the registry is voluntary. All patients who meet the protocol inclusion/exclusion criteria and who are seen within a participating physician practice are potential candidates for this registry.

Download our overview sheet

Request more information from our team

Choose Miraca for Your Patients


Learn more about Miraca's Anatomic Pathology services

Learn More »

The Miraca support team is always available, even if it’s a quick text. I cannot stress enough how great it is to know someone is always there, especially when it came time to attest for Meaningful Use and PQRS. It was my first year attesting for our practice and was a day I initially dreaded. Kimberly Johnson and Amy Schmid helped me run reports each month to make sure our practice was on track, then came in and made attestation look easy. They are so knowledgeable. Then to top it off, we have our sales rep, Laura Richards, who is always available when we need her and happy to help. I can’t imagine our practice without EMA and our Miraca team. Thank you for going above and beyond.
— Kimberly J. Wonderlich, MD,
Wonderlich Dermatology, Fairbanks, Alaska


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.